Lv4
508 积分 2021-12-30 加入
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
9天前
已完结
Tumour heterogeneity and resistance to cancer therapies
9天前
已完结
Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
9天前
已完结
Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway
9天前
已完结
Structure-guided discovery of a potent 4th-generation EGFR-TKI overcoming osimertinib-resistant C797S
9天前
已完结
The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability
9天前
已关闭
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
9天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
10天前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
14天前
已完结
Global Burden of Pulmonary Arterial Hypertension and Associated Heart Failure
9个月前
已完结
皖公网安备34019202002308
